A5 - Molecular mechanisms of hepatitis B virus persistence in chronically infected human chimeric mice

A5 und A8_April 2014

Principal Investigator:
PD Dr. rer. nat. Maura Dandri
I. Medizinische Klinik und Poliklinik
Universitätsklinikum Hamburg-Eppendorf
Martinistr. 52
20246 Hamburg
Tel.: +49-40-7410-52949
Fax: +49-40-7410-57232
E-Mail: m.dandri@uke.de

Project description
Approximately 350 Million individuals are chronically infected worldwide with the Hepatitis B Virus (HBV). Chronic infection is due to a weak immune response raised against the virus and to maintenance of the cccDNA minichromosome, the template of viral transcription. Silencing and destabilization of the cccDNA, as well as enhancement of host immune responses are necessary to clear HBV infection.

A05 in 60 SecondsVideoarchiv

A05 in 60 Seconds


Figure 2: Generation of humanized uPA/SCID mice for HBV infection studies. After cell transplantation the mouse liver is stably reconstituted with human hepatocytes (histological staining; human hepatocytes in brown) which can be infected with HBV (HBcAg staining in green).

Related news:

Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, Lohse AW, Beninati C, Pollicino T, Urban S, Lütgehetmann M, Dandri M

Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo
Gut. 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162. [Epub ahead of print]

Allweiss L, Lütgehetmann M, Dandri M

Immunofluorescent Staining for the Detection of the Hepatitis B Core Antigen in Frozen Liver Sections of Human Liver Chimeric Mice
Methods Mol Biol. 2017;1540:135-142. PubMed PMID: 27975313.

Giersch K, Allweiss L, Volz T, Dandri M, Lütgehetmann M

Serum HBV pgRNA as a clinical marker for cccDNA activity
J Hepatol. 2017 Feb;66(2):460-462. doi:10.1016/j.jhep.2016.09.028.

Autorin Maura Dandri erklärt die Publikation "Volz et al. (2013)"Videoarchiv

Autorin Maura Dandri erklärt die Publikation "Volz et al. (2013)" online seit 28.09.2013
Abb. A5
Figure 1: The HBV Life Cycle

By employing humanized uPA mice we investigated kinetics of HBV infection in vivo. We could demonstrate that host factors and therapeutically applied cytokines (peg-IFN-alpha) can directly affect the cccDNA activity.

In the future, we will study mechanisms of cccDNA clearance in regenerating hepatocytes and viral interference with cellular pathways and innate responses. To analyze interactions between HBV and components of the human immune system, new immune competent chimeric mice will be developed.